Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 352


Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales.

Andrews NJ, Waight PA, George RC, Slack MP, Miller E.

Vaccine. 2012 Nov 6;30(48):6802-8. doi: 10.1016/j.vaccine.2012.09.019. Epub 2012 Sep 18.


Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.

Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF.

Vaccine. 2013 Dec 16;31(52):6232-8. doi: 10.1016/j.vaccine.2013.10.032. Epub 2013 Oct 29.


Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine.

Miller E, Andrews NJ, Waight PA, Slack MP, George RC.

Vaccine. 2011 Nov 15;29(49):9127-31. doi: 10.1016/j.vaccine.2011.09.112. Epub 2011 Oct 5.


Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease.

Melegaro A, Choi YH, George R, Edmunds WJ, Miller E, Gay NJ.

BMC Infect Dis. 2010 Apr 8;10:90. doi: 10.1186/1471-2334-10-90.


Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.

Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MP, Miller E.

Lancet Infect Dis. 2015 May;15(5):535-43. doi: 10.1016/S1473-3099(15)70044-7. Epub 2015 Mar 20. Erratum in: Lancet Infect Dis. 2015 Jun;15(6):629.


Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012.

Demczuk WH, Martin I, Griffith A, Lefebvre B, McGeer A, Lovgren M, Tyrrell GJ, Desai S, Sherrard L, Adam H, Gilmour M, Zhanel GG; Toronto Bacterial Diseases Network; Canadian Public Health Laboratory Network.

Can J Microbiol. 2013 Dec;59(12):778-88. doi: 10.1139/cjm-2013-0614. Epub 2013 Oct 21.


Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme.

Ingels H, Rasmussen J, Andersen PH, Harboe ZB, Glismann S, Konradsen H, Hoffmann S, Valentiner-Branth P, Lambertsen L; Danish Pneumococcal Surveillance Collaboration Group 2009-2010.

Vaccine. 2012 Jun 6;30(26):3944-50. doi: 10.1016/j.vaccine.2012.03.060. Epub 2012 Apr 11.


Invasive pneumococcal disease, comorbidities, and polysaccharide vaccine use in children aged 5-15 years in England and Wales.

Ladhani SN, Andrews NJ, Waight P, Borrow R, Slack MP, Miller E.

Clin Infect Dis. 2014 Feb;58(4):517-25. doi: 10.1093/cid/cit791. Epub 2013 Dec 2.


Have changing pneumococcal vaccination programmes impacted disease in Ontario?

Lim GH, Wormsbecker AE, McGeer A, Pillai DR, Gubbay JB, Rudnick W, Low DE, Green K, Crowcroft NS, Deeks SL.

Vaccine. 2013 May 31;31(24):2680-5. doi: 10.1016/j.vaccine.2013.04.007. Epub 2013 Apr 16.


Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study.

Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele DW.

Clin Infect Dis. 2009 Jul 15;49(2):205-12. doi: 10.1086/599827.


Nearly complete elimination of the 7-valent pneumococcal conjugate vaccine serotypes in Tennessee.

Halasa NB, Grijalva CG, Arbogast PG, Talbot TR, Craig AS, Griffin MR, Schaffner W.

Pediatr Infect Dis J. 2013 Jun;32(6):604-9. doi: 10.1097/INF.0b013e318287fe0d.


Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective.

Weil-Olivier C, van der Linden M, de Schutter I, Dagan R, Mantovani L.

BMC Infect Dis. 2012 Sep 7;12:207. doi: 10.1186/1471-2334-12-207. Review.


Pneumococcal disease in South Australia: vaccine success but no time for complacency.

Johnson DR, D'Onise K, Holland RA, Raupach JC, Koehler AP.

Vaccine. 2012 Mar 9;30(12):2206-11. doi: 10.1016/j.vaccine.2011.12.119. Epub 2012 Jan 23.


7-Valent pneumococcal conjugate vaccination in England and Wales: is it still beneficial despite high levels of serotype replacement?

Choi YH, Jit M, Gay N, Andrews N, Waight PA, Melegaro A, George R, Miller E.

PLoS One. 2011;6(10):e26190. doi: 10.1371/journal.pone.0026190. Epub 2011 Oct 14.


Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study.

Miller E, Andrews NJ, Waight PA, Slack MP, George RC.

Lancet Infect Dis. 2011 Oct;11(10):760-8. doi: 10.1016/S1473-3099(11)70090-1. Epub 2011 May 27.


Impact of pneumococcal vaccines on invasive pneumococcal disease in Taiwan.

Liao WH, Lin SH, Lai CC, Tan CK, Liao CH, Huang YT, Wang CY, Hsueh PR.

Eur J Clin Microbiol Infect Dis. 2010 Apr;29(4):489-92. doi: 10.1007/s10096-010-0873-7. Epub 2010 Jan 27.


Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine.

Black S, France EK, Isaacman D, Bracken L, Lewis E, Hansen J, Fireman B, Austrian R, Graepel J, Gray S, Klein NP.

Pediatr Infect Dis J. 2007 Sep;26(9):771-7.


Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.

Lacapa R, Bliss SJ, Larzelere-Hinton F, Eagle KJ, McGinty DJ, Parkinson AJ, Santosham M, Craig MJ, O'Brien KL.

Clin Infect Dis. 2008 Aug 15;47(4):476-84. doi: 10.1086/590001.


Mathematical modelling long-term effects of replacing Prevnar7 with Prevnar13 on invasive pneumococcal diseases in England and Wales.

Choi YH, Jit M, Flasche S, Gay N, Miller E.

PLoS One. 2012;7(7):e39927. doi: 10.1371/journal.pone.0039927. Epub 2012 Jul 13.

Items per page

Supplemental Content

Write to the Help Desk